Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 8/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863276 | 0.86 | FAAH (0.45) | CES1CES2ALDH1A1FAAHMEN1 | |
| SCHEMBL2871597 | 0.84 | FAAH (0.54) | CES1CES2TSHRALDH1A1FAAH | |
| SCHEMBL29655327 | 0.84 | FAAH (0.54) | CES1CES2TSHRALDH1A1FAAH | |
| SCHEMBL2862073 | 0.82 | FAAH (0.55) | CES1CES2TSHRALDH1A1FAAH | |
| SCHEMBL2871857 | 0.82 | FAAH (0.55) | CES1CES2TSHRALDH1A1FAAH | |
| SCHEMBL5270259 | 0.80 | HDAC3 (0.43) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL2864735 | 0.79 | TDP1 (0.40) | FFAR3TSHRALDH1A1 | |
| Hydrogen Sulfide SCHEMBL28112419 | 0.78 | HDAC3 (0.42) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL25307640 | 0.77 | CES1 (0.41) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL28687646 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| CN-101115403-B | flavouring ingredient | FIRMENICH S.A. (CH) | 2011-11-30 | — | — | CN | disclosed |
| US-7794767-B2 | Flavoring ingredients | FIRMENICH SA (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-1858351-B1 | FLAVORING INGREDIENTS | FIRMENICH & CIE (CH) | 2008-11-12 | — | — | EP | disclosed |
| CN-101115403-A | Flavouring ingredient | FIRMENICH & CIE (CH) | 2008-01-30 | — | — | CN | disclosed |
| EP-1858351-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259088-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2007-11-08 | — | — | US | disclosed |
| WO-2006092749-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CES1 1136/4885CES2 843/4885HDAC3 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.